Literature DB >> 25316490

Extended surgical resection and histology in retroperitoneal sarcoma.

Aimee M Crago1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25316490     DOI： 10.1245/s10434-014-4135-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  5 in total

Review 1.  Liposarcoma: Multimodality Management and Future Targeted Therapies.

Authors:  Aimee M Crago; Mark A Dickson
Journal:  Surg Oncol Clin N Am       Date:  2016-07-30       Impact factor: 3.495

2.  Retroperitoneal sarcoma (RPS) high risk gross tumor volume boost (HR GTV boost) contour delineation agreement among NRG sarcoma radiation and surgical oncologists.

Authors:  Elizabeth H Baldini; Walter Bosch; John M Kane; Ross A Abrams; Kilian E Salerno; Curtiland Deville; Chandrajit P Raut; Ivy A Petersen; Yen-Lin Chen; John T Mullen; Keith W Millikan; Giorgos Karakousis; Michael L Kendrick; Thomas F DeLaney; Dian Wang
Journal:  Ann Surg Oncol       Date:  2015-05-28       Impact factor: 5.344

Review 3.  Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

Authors:  Alessandro De Vita; Laura Mercatali; Federica Recine; Federica Pieri; Nada Riva; Alberto Bongiovanni; Chiara Liverani; Chiara Spadazzi; Giacomo Miserocchi; Dino Amadori; Toni Ibrahim
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

4.  Leiomyosarcoma of the renal vein: analysis of outcome and prognostic factors in the world case series of 67 patients.

Authors:  Marko Novak; Andraz Perhavec; Katherine E Maturen; Snezana Pavlovic Djokic; Simona Jereb; Darja Erzen
Journal:  Radiol Oncol       Date:  2016-12-23       Impact factor: 2.991

5.  Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma.

Authors:  Michael J Nathenson; Constance M Barysauskas; Robert A Nathenson; William F Regine; Nader Hanna; Edward Sausville
Journal:  World J Surg Oncol       Date:  2018-10-11       Impact factor: 2.754
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.